Unified clinical trial software for hematology studies

One platform. Aligned hematology data. Built for complex, lab intensive research.



oomnia brings hematology trials into a unified Clinical Research Information System (CRIS), allowing teams to coordinate laboratory data, clinical outcomes, and safety monitoring within a single environment. This ensures consistent tracking of disease progression and treatment response across hematology studies.

The operational reality of hematology clinical trials

Highly heterogeneous patient populations

Hematology studies span diverse diseases with significant variability in genetics, disease stage, prior treatments, and response patterns

Dependence on continuous laboratory monitoring

Trial decisions often depend on frequent lab results, including hematology panels, biomarkers, and genetic testing

Complex and evolving treatment pathways

Treatment regimens, dosing, and endpoints may change during the study, increasing execution complexity

Long study durations and follow-up requirements

Many hematology trials require extended observation to assess durability of response, survival outcomes, or relapse, creating challenges

High operational and site burden

Frequent visits, transfusions, safety checks, and data entry demands place pressure on sites, requiring efficient workflows to maintain compliance and data quality

One connected system for hematology trial execution

Aligns laboratory results, clinical outcomes, and safety data within a unified dataset

Supports protocol adjustments as dosing strategies, endpoints, or assessment schedules evolve

Enables continuous visibility into patient response, relapse, and adverse events over time

Connects sites, laboratories, and sponsors within a single coordinated platform

One platform for hematology trial execution

Hematology workflows, connected from the start

oomnia unifies laboratory integration, clinical data capture, and operational processes into one system, ensuring that patient data, safety signals, and study activities remain synchronized and accessible across all stakeholders

EDC

Captures hematology specific data such as longitudinal lab values, transfusion records, disease response criteria, and adverse events, with structured validation to ensure consistency

CTMS

Provides end-to-end oversight of study progress, site performance, and operational milestones across hematology programs

RTSM

Supports complex allocation strategies, including adaptive designs, cohort management, and treatment assignment based on disease characteristics

eConsent

Facilitates patient onboarding and consent updates, supporting both on-site and remote participation in trials with intensive monitoring schedules

eCOA / ePRO

Captures patient reported symptoms, treatment side effects, and quality-of-life changes throughout long-term studies

eTMF

Maintains complete, audit ready documentation across evolving hematology protocols and regulatory requirements

Patient engagement tools

Supports adherence through automated reminders and communication tailored to frequent visits, lab tests, and follow-up assessments

Analytics and reporting

Combines laboratory data, clinical outcomes, and safety signals into real-time dashboards for ongoing monitoring and decision making

EDC: Electronic Data Capture; CTMS: Clinical Trial Management System; RTSM: Randomization and Trial Supply Management; eConsent: Electronic Informed Consent; eCOA/ePRO: Electronic Clinical Outcome Assessment / Electronic Patient-Reported Outcome; eTMF: Electronic Trial Master File.

How oomnia fits into the hematology study ecosystem

oomnia provides a centralized framework connecting investigative sites, central and specialty laboratories, safety teams, and sponsor systems. This ensures that all hematology data, clinical, laboratory, and operational, flows consistently across participants and stakeholders.

Built for regulatory and operational confidence

- 21 CFR Part 11–compliant records with secure electronic signatures and complete audit trails
- Risk based quality management aligned with ICH E6(R3) guidance
- CDISC-aligned datasets supporting hematology endpoints and regulatory submissions
- Designed for multiregional trials and global regulatory interactions

Measurable impact for hematology clinical teams

More consistent tracking of patient outcomes

Unified data capture across lab results, safety monitoring, and clinical endpoints improves reliability in assessing treatment effects

Improved visibility across complex datasets

Integrated dashboards provide a complete view of longitudinal patient data, enabling earlier detection of trends and risks

Reduced operational complexity

A single platform replaces multiple disconnected systems, simplifying coordination between sites, labs, and sponsors

Stronger data integrity in long-term studies

Structured validation and unified workflows minimize discrepancies across extended timelines and repeated assessments

ICH E6(R3): International Council for Harmonisation Guideline for Good Clinical Practice (Revision 3); CDISC: Clinical Data Interchange Standards Consortium; 21 CFR Part 11: Title 21 Code of Federal Regulations Part 11 (Electronic Records and Electronic Signatures).

Explore how oomnia supports hematology trials

Request a demo

Wemedoo
Clinical Information Specialists

info@wemedoo.com
+41 41 740 0124
Wemedoo AG
www.wemedoo.com